US20070088077A1 - Appetite stimulation and reduction of weight loss in patients suffering from symptomatic hiv infection - Google Patents

Appetite stimulation and reduction of weight loss in patients suffering from symptomatic hiv infection Download PDF

Info

Publication number
US20070088077A1
US20070088077A1 US11/537,914 US53791406A US2007088077A1 US 20070088077 A1 US20070088077 A1 US 20070088077A1 US 53791406 A US53791406 A US 53791406A US 2007088077 A1 US2007088077 A1 US 2007088077A1
Authority
US
United States
Prior art keywords
patient
delta
tetrahydrocannabinol
human patient
hiv infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/537,914
Inventor
Terry Plasse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unimed Pharmaceuticals LLC
Original Assignee
Plasse Terry F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plasse Terry F filed Critical Plasse Terry F
Priority to US11/537,914 priority Critical patent/US20070088077A1/en
Publication of US20070088077A1 publication Critical patent/US20070088077A1/en
Assigned to UNIMED PHARMACEUTICALS, LLC reassignment UNIMED PHARMACEUTICALS, LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: UNIMED PHARMACEUTICALS, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Definitions

  • HIV infection includes inter alia AIDS (Acquired Immune Deficiency Syndrome) and ARC (AIDS Related Complex), are loss of appetite with consequent loss of weight. This loss of appetite and loss of weight further debilitates the patients and increases the many problems associated with the HIV infection.
  • AIDS Abnormal Immune Deficiency Syndrome
  • ARC AIDS Related Complex
  • the compound delta-9-tetrahydrocannabinol which is the active ingredient in marijuana and which was produced chemically as described in U.S. Pat. No. 3,668,224, has been used as an antiemetic to relieve nausea and vomiting in patients receiving cancer chemotherapy.
  • delta-9-tetrahydrocannabinol A number of cancer investigators have used delta-9-tetrahydrocannabinol to attempt to increase appetite and modify weight loss in cancer patients. For example, in a randomized double-blind crossover study employing oral delta-9-tetrahydrocannabinol and prochlorperazine, 50% of the subjects on delta-9-tetrahydrocannabinol reported an increased food intake while only 29% had a similar response on the prochlorperazine. 1 In another study of similar design and using the same medications, patients on delta-9-tetrahydrocannabinol reported feeling more hungry than patients on prochlorperazine. 2 Results suggestive of an appetite stimulating effect were also noted by Ekert, et al.
  • Wadleigh, et al. 5 observed appetite increases and a lessening of the rate of weight loss in cancer patients. 5 Wadleigh, R; Spaulding, M; Lembersky, B; Zimmer. M: Shepard, K; Plasse, T; Dronabinol enhancement of appetite in cancer patients. Proceedings 1990 American Cancer Society of Clinical Mycology Meeting.
  • the present invention mainly comprises the administration to a patient suffering from symptomatic HIV infection of an appetite stimulating effective amount of delta-9-tetrahydrocannabinol.
  • the delta-9-tetrahydrocannabinol is preferably administered orally as dronabinol (delta-9-tetrahydrocannabinol in sesame oil-containing capsules). Administration is also possible to achieve the effects of the present invention when the delta-9-tetrahydrocannabinol is in the form of tablets, suppositories, intranasal administration, transdermal administration, inhalants and sublingual administration, as well as administration by injection.
  • delta-9-tetrahydrocannabinol may vary widely from 2.5 mg to 20 mg daily, in single or divided doses.
  • Soft gelatin capsules were filled with delta-9-tetrahydrocannabinol in sesame oil (dronabinol).
  • Capsules were filled with 2.5 mg delta-9-tetrahydrocannabinol per capsule or 5 mg delta-9-tetrahydrocannabinol per capsule.
  • Example I At a dose which appears optimal, seven of eight patients completed one month treatment. At that dose, most patients did not experience side effects. Most of those patients who did experience side effects found them tolerable. Confirming the unexpected results of Example I, five of the seven patients gained weight.
  • the median rate of weight loss prior to therapy was 1.62 kg/mo; on therapy, the median weight gain was 1.56 kg/mo.
  • the median improvement in the rate of weight change was 3.06 kg/mo, or approximately 1.5 lbs/wk.
  • delta-9-tetrahydrocannabinol can provide a significant tool in the treatment of patients with symptomatic HIV infection by improving appetite and reducing weight loss.

Abstract

Patients with symptomatic HIV infection, including AIDS and ARC are treated to increase appetite and to cause a reduction in loss of weight. The delta-9-tetrahydrocannabinol may be administered orally, in capsules, or in tablets, or by injection, suppository, intranasal, transdermal, inhalant or sublingual administration.

Description

    RELATED CASES
  • This application is a continuation of and claims priority to U.S. application Ser. No. 10/735,017, filed Dec. 12, 2003, which is a continuation of U.S. application Ser. No. 07/893,554, filed Jun. 3, 1992, which is a continuation of U.S. application Ser. No. 07/661,514, filed Feb. 26, 1991, all of which are incorporated herein by reference in their entirety to the extent permitted by law.
    • BACKGROUND OF THE INVENTION
  • Among the many problems endured by patients suffering from symptomatic HIV infection, which includes inter alia AIDS (Acquired Immune Deficiency Syndrome) and ARC (AIDS Related Complex), are loss of appetite with consequent loss of weight. This loss of appetite and loss of weight further debilitates the patients and increases the many problems associated with the HIV infection.
  • The compound delta-9-tetrahydrocannabinol, which is the active ingredient in marijuana and which was produced chemically as described in U.S. Pat. No. 3,668,224, has been used as an antiemetic to relieve nausea and vomiting in patients receiving cancer chemotherapy.
  • A number of cancer investigators have used delta-9-tetrahydrocannabinol to attempt to increase appetite and modify weight loss in cancer patients. For example, in a randomized double-blind crossover study employing oral delta-9-tetrahydrocannabinol and prochlorperazine, 50% of the subjects on delta-9-tetrahydrocannabinol reported an increased food intake while only 29% had a similar response on the prochlorperazine.1 In another study of similar design and using the same medications, patients on delta-9-tetrahydrocannabinol reported feeling more hungry than patients on prochlorperazine.2 Results suggestive of an appetite stimulating effect were also noted by Ekert, et al.3 in groups of children and adolescents 6-19 years of age administered delta-9-tetrahydrocannabinol, prochlorperazine or metaclopramide in crossover design studies.
    1 Sallan, S E; Cronin, C; Zelan, M; and Zinberg, N E (Sidney Farber Cancer Institute, Boston, Mass.): Antiemetics in patients receiveing chemotherapy for cancer. A prochlorperazine. N. Engl. J. Med. 301:135-138 (Jan. 17) 1980, No. 3.

    2 Ungerleider, J T; Andrysiak, T; Fairbanks, L; Gooodnight, J; Sarna, G; and Jamison, K. (UCLA Center for the Health Sciences, Los Angeles, Calif.): Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine. Cancer 50:636-645 (Aug. 15) 1982, No. 4.

    3 Ekert, H; Waters, K D; Jurk, I H; Mobilia, J; and Loughnan, P. (Royal Children's Hospital, Melbourne, Australia): Amerlioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med. J. Aust. 2:657-659 (Dec. 15) 1979.
  • In a double blind study, Regelson, et al.4 observed that advanced cancer patients on chemotherapy receiving delta-9-tetrahydrocannabinol maintained their weight better than those
    4 Regelson W, Butter J R; Schultz J; Kirk T; Peek L; Green M L; Delta-9-tetrahydrocannabinol, (delta-9-THC) as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. The pharmacology of marihuana, (Braude M C & Szara S eds) Raven Press, N.Y. (1976; pp. 763-766.
  • not receiving the delta-9-tetrahydrocannabinol.
  • In an open study, Wadleigh, et al.5 observed appetite increases and a lessening of the rate of weight loss in cancer patients.
    5 Wadleigh, R; Spaulding, M; Lembersky, B; Zimmer. M: Shepard, K; Plasse, T; Dronabinol enhancement of appetite in cancer patients. Proceedings 1990 American Cancer Society of Clinical Mycology Meeting.
    • SUMMARY OF THE INVENTION
  • It is accordingly a primary object of the present invention to provide for the treatment of patients suffering from symptomatic HIV infection so as to improve the appetite and reduce weight loss in such patients.
  • Other objects and advantages of the present invention will be apparent from a further reading of the specification and of the appended claims.
  • With the above and other objects in view, the present invention mainly comprises the administration to a patient suffering from symptomatic HIV infection of an appetite stimulating effective amount of delta-9-tetrahydrocannabinol.
  • The delta-9-tetrahydrocannabinol is preferably administered orally as dronabinol (delta-9-tetrahydrocannabinol in sesame oil-containing capsules). Administration is also possible to achieve the effects of the present invention when the delta-9-tetrahydrocannabinol is in the form of tablets, suppositories, intranasal administration, transdermal administration, inhalants and sublingual administration, as well as administration by injection.
  • The dosage range of delta-9-tetrahydrocannabinol may vary widely from 2.5 mg to 20 mg daily, in single or divided doses.
    • DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • The following is given to further illustrate the present invention. The scope of the invention is not, however, meant to be limited to the specific details thereof.
    • EXAMPLE I
  • Soft gelatin capsules were filled with delta-9-tetrahydrocannabinol in sesame oil (dronabinol). Capsules were filled with 2.5 mg delta-9-tetrahydrocannabinol per capsule or 5 mg delta-9-tetrahydrocannabinol per capsule.
  • Ten symptomatic HIV patients were treated with delta-9-tetrahydrocannabinol. The patients studied were all homosexual males; one had a history of intravenous drug abuse as well. The infectious complications which they had represent the spectrum of those usually seen in a symptomatic HIV-infected population.
  • Most of the patients had received or were on antiviral therapy, primarily zidovudine (azidothymidine). Two had previously received and one was receiving megesterol acetate as well. Patients received delta-9-tetrahydrocannabinol as dronabinol (delta-9-tetrahydrocannabinol in sesame oil in soft gelatin capsules), usually at a dose of 2.5 mg, for one to five months. Treatment continued for most of the patients at the time of this analysis. The dose varied. The patients were instructed to take medication up to four times daily as needed; many took it somewhat less often.
  • Initially, patients were losing a median of 0.93 kg/mo. On therapy, they gained 0.54 kg/mo. The median difference on versus pre-therapy was 1.92 kg/mo. Seven patients gained weight while two others had a decrease in weight loss. This result was unexpected as previous studies in cancer patients showed that while weight loss lessened, patients rarely gained weight.
    • EXAMPLE II
  • In a prospective, dose-ranging study, 23 patients with symptomatic HIV infection were treated with dronabinol at a dose of 2.5 mg twice daily to 5.0 mg three times daily. Of these, 13 completed approximately one month on therapy. Of those completing one month on therapy, seven gained weight.
  • At a dose which appears optimal, seven of eight patients completed one month treatment. At that dose, most patients did not experience side effects. Most of those patients who did experience side effects found them tolerable. Confirming the unexpected results of Example I, five of the seven patients gained weight. The median rate of weight loss prior to therapy was 1.62 kg/mo; on therapy, the median weight gain was 1.56 kg/mo. The median improvement in the rate of weight change was 3.06 kg/mo, or approximately 1.5 lbs/wk.
  • It thus appears that delta-9-tetrahydrocannabinol can provide a significant tool in the treatment of patients with symptomatic HIV infection by improving appetite and reducing weight loss.
  • While the invention has been illustrated with respect to specific dosages, it is apparent that variations and modifications can be made without departing from the spirit or scope of the invention.

Claims (16)

1. A method of treating a human patient with symptomatic HIV infection to stimulate weight gain in the patient, the method comprising orally administering to the patient a pharmaceutical composition comprising dronabinol, wherein the dronabinol is present in the composition in a total amount of about 2.5 mg to about 20 mg.
2. The method of claim 1, wherein the human patient is male.
3. The method of claim 1, wherein the weight gain comprises an weight change of approximately 1.5 lbs/week.
4. A method of treating a human patient with symptomatic HIV infection to stimulate weight gain in the patient comprising:
providing to the patient delta-9-tetrahydrocannabinol in a dosing regimen optimized to minimize side effects.
5. The method of claim 4, wherein the weight gain comprises a weight change of approximately 1.5 lbs/week.
6. The method of claim 4, wherein the side effects comprise nausea.
7. The method of claim 4, wherein the side effects comprise CNS effects.
8. The method of claim 4, wherein the human patient is male.
9. The method of claim 1, wherein the human patient is on antiviral therapy.
10. The method of claim 9, wherein the anti-viral therapy comprises azidothymidine.
11. The method of claim 9, wherein the anti-viral therapy comprises megesterol acetate.
12. The method of claim 1, wherein the human patient had received anti-viral therapy.
13. A method of treating a human patient to stimulate weight gain comprising:
administering to the patient an effective amount of delta-9-tetrahydrocannabinol.
14. A method of treating a human patient with symptomatic HIV infection to stimulate weight gain in the patient comprising:
administering to the patient an appetite-stimulating effective amount of delta-9-tetrahydrocannabinol in conjunction with at least one additional medication.
15. The method of claim 14, wherein said additional medication comprises an antiviral therapy.
16. A method of treating an HIV human patient comprising:
administering an effective amount of delta-9-tetrahydrocannabinol.
US11/537,914 1991-02-26 2006-10-02 Appetite stimulation and reduction of weight loss in patients suffering from symptomatic hiv infection Abandoned US20070088077A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/537,914 US20070088077A1 (en) 1991-02-26 2006-10-02 Appetite stimulation and reduction of weight loss in patients suffering from symptomatic hiv infection

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66151491A 1991-02-26 1991-02-26
US07/893,554 US6703418B2 (en) 1991-02-26 1992-06-03 Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US10/735,017 US20040209944A1 (en) 1991-02-26 2003-12-12 Appetite stimulation and reduction of weight loss in patients suffering from symptomatic HIV infection
US11/537,914 US20070088077A1 (en) 1991-02-26 2006-10-02 Appetite stimulation and reduction of weight loss in patients suffering from symptomatic hiv infection

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/735,017 Continuation US20040209944A1 (en) 1991-02-26 2003-12-12 Appetite stimulation and reduction of weight loss in patients suffering from symptomatic HIV infection

Publications (1)

Publication Number Publication Date
US20070088077A1 true US20070088077A1 (en) 2007-04-19

Family

ID=24653916

Family Applications (3)

Application Number Title Priority Date Filing Date
US07/893,554 Expired - Lifetime US6703418B2 (en) 1991-02-26 1992-06-03 Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US10/735,017 Abandoned US20040209944A1 (en) 1991-02-26 2003-12-12 Appetite stimulation and reduction of weight loss in patients suffering from symptomatic HIV infection
US11/537,914 Abandoned US20070088077A1 (en) 1991-02-26 2006-10-02 Appetite stimulation and reduction of weight loss in patients suffering from symptomatic hiv infection

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US07/893,554 Expired - Lifetime US6703418B2 (en) 1991-02-26 1992-06-03 Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
US10/735,017 Abandoned US20040209944A1 (en) 1991-02-26 2003-12-12 Appetite stimulation and reduction of weight loss in patients suffering from symptomatic HIV infection

Country Status (1)

Country Link
US (3) US6703418B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060160888A1 (en) * 2004-12-09 2006-07-20 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
US20090181080A1 (en) * 2007-08-06 2009-07-16 Insys Therapeutics Inc. Oral cannabinnoid liquid formulations and methods of treatment

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004287495A1 (en) * 2003-11-05 2005-05-19 Unimed Pharmaceuticals, Inc. Delta-9- the treatment of multiple sclerosis
TWI436991B (en) * 2004-11-22 2014-05-11 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
US20060258738A1 (en) * 2005-05-12 2006-11-16 Douglas Dieterich Use of dronabinol for treatment of side effects of Hepatitis C therapy
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070060639A1 (en) * 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
WO2012068516A2 (en) * 2010-11-18 2012-05-24 Pier Pharmaceuticals Low dose cannabinoid medicaments
EP2654864B1 (en) 2010-12-22 2020-10-28 Syqe Medical Ltd. System for drug delivery
WO2015200049A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
RU2690401C2 (en) 2014-06-30 2019-06-03 Сике Медикал Лтд. Method and device for evaporation and inhalation of released substances
AU2015283590B2 (en) 2014-06-30 2020-04-16 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
KR20230117250A (en) 2014-06-30 2023-08-07 사이키 메디컬 엘티디. Drug dose cartridge for an inhaler device
PL3160565T3 (en) 2014-06-30 2022-01-10 Syqe Medical Ltd. Devices and systems for pulmonary delivery of active agents
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
EP3656427A1 (en) 2014-06-30 2020-05-27 Syqe Medical Ltd. Flow regulating inhaler device
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
BR102015024165A2 (en) * 2015-09-18 2017-03-28 Prati Donaduzzi & Cia Ltda oral pharmaceutical composition comprising cannabinoid, process for its preparation and use
ES2874087T3 (en) 2016-01-06 2021-11-04 Syqe Medical Ltd Low-dose therapeutic treatment
CA3044812A1 (en) * 2016-10-24 2018-05-03 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione
US10702495B2 (en) 2017-02-20 2020-07-07 Nexien Biopharma, Inc. Method and compositions for treating dystrophies and myotonia
EP3750528A1 (en) 2019-06-11 2020-12-16 Nexien Biopharma, Inc. Compositions for treating dystrophies and myotonia

Citations (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
US6292678B1 (en) * 1999-05-13 2001-09-18 Stereotaxis, Inc. Method of magnetically navigating medical devices with magnetic fields and gradients, and medical devices adapted therefor
US6296604B1 (en) * 1999-03-17 2001-10-02 Stereotaxis, Inc. Methods of and compositions for treating vascular defects
US6304768B1 (en) * 1997-11-12 2001-10-16 Stereotaxis, Inc. Method and apparatus using shaped field of repositionable magnet to guide implant
US20010038683A1 (en) * 1998-11-03 2001-11-08 Ritter Rogers C. Open field system for magnetic surgery
US6315709B1 (en) * 1998-08-07 2001-11-13 Stereotaxis, Inc. Magnetic vascular defect treatment system
US6330467B1 (en) * 1999-02-04 2001-12-11 Stereotaxis, Inc. Efficient magnet system for magnetically-assisted surgery
US20020019644A1 (en) * 1999-07-12 2002-02-14 Hastings Roger N. Magnetically guided atherectomy
US6352363B1 (en) * 2001-01-16 2002-03-05 Stereotaxis, Inc. Shielded x-ray source, method of shielding an x-ray source, and magnetic surgical system with shielded x-ray source
US6375606B1 (en) * 1999-03-17 2002-04-23 Stereotaxis, Inc. Methods of and apparatus for treating vascular defects
US6385472B1 (en) * 1999-09-10 2002-05-07 Stereotaxis, Inc. Magnetically navigable telescoping catheter and method of navigating telescoping catheter
US6401723B1 (en) * 2000-02-16 2002-06-11 Stereotaxis, Inc. Magnetic medical devices with changeable magnetic moments and method of navigating magnetic medical devices with changeable magnetic moments
US6428551B1 (en) * 1999-03-30 2002-08-06 Stereotaxis, Inc. Magnetically navigable and/or controllable device for removing material from body lumens and cavities
US6459924B1 (en) * 1997-11-12 2002-10-01 Stereotaxis, Inc. Articulated magnetic guidance systems and devices and methods for using same for magnetically-assisted surgery
US20020177789A1 (en) * 2001-05-06 2002-11-28 Ferry Steven J. System and methods for advancing a catheter
US6505062B1 (en) * 1998-02-09 2003-01-07 Stereotaxis, Inc. Method for locating magnetic implant by source field
US6522909B1 (en) * 1998-08-07 2003-02-18 Stereotaxis, Inc. Method and apparatus for magnetically controlling catheters in body lumens and cavities
US6524303B1 (en) * 2000-09-08 2003-02-25 Stereotaxis, Inc. Variable stiffness magnetic catheter
US6537196B1 (en) * 2000-10-24 2003-03-25 Stereotaxis, Inc. Magnet assembly with variable field directions and methods of magnetically navigating medical objects
US6562019B1 (en) * 1999-09-20 2003-05-13 Stereotaxis, Inc. Method of utilizing a magnetically guided myocardial treatment system
US6662034B2 (en) * 2000-11-15 2003-12-09 Stereotaxis, Inc. Magnetically guidable electrophysiology catheter
US6677752B1 (en) * 2000-11-20 2004-01-13 Stereotaxis, Inc. Close-in shielding system for magnetic medical treatment instruments
US20040019447A1 (en) * 2002-07-16 2004-01-29 Yehoshua Shachar Apparatus and method for catheter guidance control and imaging
US6702804B1 (en) * 1999-10-04 2004-03-09 Stereotaxis, Inc. Method for safely and efficiently navigating magnetic devices in the body
US20040068173A1 (en) * 2002-08-06 2004-04-08 Viswanathan Raju R. Remote control of medical devices using a virtual device interface
US6733511B2 (en) * 1998-10-02 2004-05-11 Stereotaxis, Inc. Magnetically navigable and/or controllable device for removing material from body lumens and cavities
US20040096511A1 (en) * 2002-07-03 2004-05-20 Jonathan Harburn Magnetically guidable carriers and methods for the targeted magnetic delivery of substances in the body
US20040133130A1 (en) * 2003-01-06 2004-07-08 Ferry Steven J. Magnetically navigable medical guidewire
US20040157082A1 (en) * 2002-07-22 2004-08-12 Ritter Rogers C. Coated magnetically responsive particles, and embolic materials using coated magnetically responsive particles
US20040158972A1 (en) * 2002-11-07 2004-08-19 Creighton Francis M. Method of making a compound magnet
US20040186376A1 (en) * 2002-09-30 2004-09-23 Hogg Bevil J. Method and apparatus for improved surgical navigation employing electronic identification with automatically actuated flexible medical devices
US6817364B2 (en) * 2000-07-24 2004-11-16 Stereotaxis, Inc. Magnetically navigated pacing leads, and methods for delivering medical devices
US20040249263A1 (en) * 2003-03-13 2004-12-09 Creighton Francis M. Magnetic navigation system and magnet system therefor
US20040249262A1 (en) * 2003-03-13 2004-12-09 Werp Peter R. Magnetic navigation system
US6834201B2 (en) * 2001-01-29 2004-12-21 Stereotaxis, Inc. Catheter navigation within an MR imaging device
US20040260172A1 (en) * 2003-04-24 2004-12-23 Ritter Rogers C. Magnetic navigation of medical devices in magnetic fields
US20050020911A1 (en) * 2002-04-10 2005-01-27 Viswanathan Raju R. Efficient closed loop feedback navigation
US20050043611A1 (en) * 2003-05-02 2005-02-24 Sabo Michael E. Variable magnetic moment MR navigation
US20050065435A1 (en) * 2003-07-22 2005-03-24 John Rauch User interface for remote control of medical devices
US20050096589A1 (en) * 2003-10-20 2005-05-05 Yehoshua Shachar System and method for radar-assisted catheter guidance and control
US20050113628A1 (en) * 2002-01-23 2005-05-26 Creighton Francis M.Iv Rotating and pivoting magnet for magnetic navigation
US20050113812A1 (en) * 2003-09-16 2005-05-26 Viswanathan Raju R. User interface for remote control of medical devices
US20050119687A1 (en) * 2003-09-08 2005-06-02 Dacey Ralph G.Jr. Methods of, and materials for, treating vascular defects with magnetically controllable hydrogels
US6902528B1 (en) * 1999-04-14 2005-06-07 Stereotaxis, Inc. Method and apparatus for magnetically controlling endoscopes in body lumens and cavities
US20050182315A1 (en) * 2003-11-07 2005-08-18 Ritter Rogers C. Magnetic resonance imaging and magnetic navigation systems and methods
US20050256398A1 (en) * 2004-05-12 2005-11-17 Hastings Roger N Systems and methods for interventional medicine
US6968846B2 (en) * 2002-03-07 2005-11-29 Stereotaxis, Inc. Method and apparatus for refinably accurate localization of devices and instruments in scattering environments
US6975197B2 (en) * 2002-01-23 2005-12-13 Stereotaxis, Inc. Rotating and pivoting magnet for magnetic navigation
US6980843B2 (en) * 2003-05-21 2005-12-27 Stereotaxis, Inc. Electrophysiology catheter
US20060009735A1 (en) * 2004-06-29 2006-01-12 Viswanathan Raju R Navigation of remotely actuable medical device using control variable and length
US20060025679A1 (en) * 2004-06-04 2006-02-02 Viswanathan Raju R User interface for remote control of medical devices
US20060036163A1 (en) * 2004-07-19 2006-02-16 Viswanathan Raju R Method of, and apparatus for, controlling medical navigation systems
US20060041245A1 (en) * 2001-05-06 2006-02-23 Ferry Steven J Systems and methods for medical device a dvancement and rotation
US7008418B2 (en) * 2002-05-09 2006-03-07 Stereotaxis, Inc. Magnetically assisted pulmonary vein isolation
US20060058646A1 (en) * 2004-08-26 2006-03-16 Raju Viswanathan Method for surgical navigation utilizing scale-invariant registration between a navigation system and a localization system
US7019610B2 (en) * 2002-01-23 2006-03-28 Stereotaxis, Inc. Magnetic navigation system
US7020512B2 (en) * 2002-01-14 2006-03-28 Stereotaxis, Inc. Method of localizing medical devices
US20060074297A1 (en) * 2004-08-24 2006-04-06 Viswanathan Raju R Methods and apparatus for steering medical devices in body lumens
US20060079745A1 (en) * 2004-10-07 2006-04-13 Viswanathan Raju R Surgical navigation with overlay on anatomical images
US20060079812A1 (en) * 2004-09-07 2006-04-13 Viswanathan Raju R Magnetic guidewire for lesion crossing
US20060093193A1 (en) * 2004-10-29 2006-05-04 Viswanathan Raju R Image-based medical device localization
US20060094956A1 (en) * 2004-10-29 2006-05-04 Viswanathan Raju R Restricted navigation controller for, and methods of controlling, a remote navigation system
US20060100505A1 (en) * 2004-10-26 2006-05-11 Viswanathan Raju R Surgical navigation using a three-dimensional user interface
US7066924B1 (en) * 1997-11-12 2006-06-27 Stereotaxis, Inc. Method of and apparatus for navigating medical devices in body lumens by a guide wire with a magnetic tip
US20060144407A1 (en) * 2004-07-20 2006-07-06 Anthony Aliberto Magnetic navigation manipulation apparatus
US20060144408A1 (en) * 2004-07-23 2006-07-06 Ferry Steven J Micro-catheter device and method of using same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055446A (en) * 1988-10-21 1991-10-08 University Of Cincinnati Method to improve survival of patients during sepsis by diet composition
NZ333399A (en) * 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis

Patent Citations (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
US6304768B1 (en) * 1997-11-12 2001-10-16 Stereotaxis, Inc. Method and apparatus using shaped field of repositionable magnet to guide implant
US6507751B2 (en) * 1997-11-12 2003-01-14 Stereotaxis, Inc. Method and apparatus using shaped field of repositionable magnet to guide implant
US7066924B1 (en) * 1997-11-12 2006-06-27 Stereotaxis, Inc. Method of and apparatus for navigating medical devices in body lumens by a guide wire with a magnetic tip
US6459924B1 (en) * 1997-11-12 2002-10-01 Stereotaxis, Inc. Articulated magnetic guidance systems and devices and methods for using same for magnetically-assisted surgery
US7010338B2 (en) * 1998-02-09 2006-03-07 Stereotaxis, Inc. Device for locating magnetic implant by source field
US6505062B1 (en) * 1998-02-09 2003-01-07 Stereotaxis, Inc. Method for locating magnetic implant by source field
US6315709B1 (en) * 1998-08-07 2001-11-13 Stereotaxis, Inc. Magnetic vascular defect treatment system
US6522909B1 (en) * 1998-08-07 2003-02-18 Stereotaxis, Inc. Method and apparatus for magnetically controlling catheters in body lumens and cavities
US6733511B2 (en) * 1998-10-02 2004-05-11 Stereotaxis, Inc. Magnetically navigable and/or controllable device for removing material from body lumens and cavities
US20010038683A1 (en) * 1998-11-03 2001-11-08 Ritter Rogers C. Open field system for magnetic surgery
US20040064153A1 (en) * 1999-02-04 2004-04-01 Creighton Francis M. Efficient magnet system for magnetically-assisted surgery
US6630879B1 (en) * 1999-02-04 2003-10-07 Stereotaxis, Inc. Efficient magnet system for magnetically-assisted surgery
US6330467B1 (en) * 1999-02-04 2001-12-11 Stereotaxis, Inc. Efficient magnet system for magnetically-assisted surgery
US6375606B1 (en) * 1999-03-17 2002-04-23 Stereotaxis, Inc. Methods of and apparatus for treating vascular defects
US6364823B1 (en) * 1999-03-17 2002-04-02 Stereotaxis, Inc. Methods of and compositions for treating vascular defects
US6296604B1 (en) * 1999-03-17 2001-10-02 Stereotaxis, Inc. Methods of and compositions for treating vascular defects
US6428551B1 (en) * 1999-03-30 2002-08-06 Stereotaxis, Inc. Magnetically navigable and/or controllable device for removing material from body lumens and cavities
US6902528B1 (en) * 1999-04-14 2005-06-07 Stereotaxis, Inc. Method and apparatus for magnetically controlling endoscopes in body lumens and cavities
US6292678B1 (en) * 1999-05-13 2001-09-18 Stereotaxis, Inc. Method of magnetically navigating medical devices with magnetic fields and gradients, and medical devices adapted therefor
US20020019644A1 (en) * 1999-07-12 2002-02-14 Hastings Roger N. Magnetically guided atherectomy
US6911026B1 (en) * 1999-07-12 2005-06-28 Stereotaxis, Inc. Magnetically guided atherectomy
US6385472B1 (en) * 1999-09-10 2002-05-07 Stereotaxis, Inc. Magnetically navigable telescoping catheter and method of navigating telescoping catheter
US20040006301A1 (en) * 1999-09-20 2004-01-08 Sell Jonathan C. Magnetically guided myocardial treatment system
US6562019B1 (en) * 1999-09-20 2003-05-13 Stereotaxis, Inc. Method of utilizing a magnetically guided myocardial treatment system
US6755816B2 (en) * 1999-10-04 2004-06-29 Stereotaxis, Inc. Method for safely and efficiently navigating magnetic devices in the body
US20040199074A1 (en) * 1999-10-04 2004-10-07 Ritter Rogers C. Method for safely and efficiently navigating magnetic devices in the body
US6702804B1 (en) * 1999-10-04 2004-03-09 Stereotaxis, Inc. Method for safely and efficiently navigating magnetic devices in the body
US6401723B1 (en) * 2000-02-16 2002-06-11 Stereotaxis, Inc. Magnetic medical devices with changeable magnetic moments and method of navigating magnetic medical devices with changeable magnetic moments
US6817364B2 (en) * 2000-07-24 2004-11-16 Stereotaxis, Inc. Magnetically navigated pacing leads, and methods for delivering medical devices
US6524303B1 (en) * 2000-09-08 2003-02-25 Stereotaxis, Inc. Variable stiffness magnetic catheter
US6537196B1 (en) * 2000-10-24 2003-03-25 Stereotaxis, Inc. Magnet assembly with variable field directions and methods of magnetically navigating medical objects
US6662034B2 (en) * 2000-11-15 2003-12-09 Stereotaxis, Inc. Magnetically guidable electrophysiology catheter
US6677752B1 (en) * 2000-11-20 2004-01-13 Stereotaxis, Inc. Close-in shielding system for magnetic medical treatment instruments
US6352363B1 (en) * 2001-01-16 2002-03-05 Stereotaxis, Inc. Shielded x-ray source, method of shielding an x-ray source, and magnetic surgical system with shielded x-ray source
US6834201B2 (en) * 2001-01-29 2004-12-21 Stereotaxis, Inc. Catheter navigation within an MR imaging device
US20020177789A1 (en) * 2001-05-06 2002-11-28 Ferry Steven J. System and methods for advancing a catheter
US20060041245A1 (en) * 2001-05-06 2006-02-23 Ferry Steven J Systems and methods for medical device a dvancement and rotation
US7020512B2 (en) * 2002-01-14 2006-03-28 Stereotaxis, Inc. Method of localizing medical devices
US7019610B2 (en) * 2002-01-23 2006-03-28 Stereotaxis, Inc. Magnetic navigation system
US6975197B2 (en) * 2002-01-23 2005-12-13 Stereotaxis, Inc. Rotating and pivoting magnet for magnetic navigation
US20050113628A1 (en) * 2002-01-23 2005-05-26 Creighton Francis M.Iv Rotating and pivoting magnet for magnetic navigation
US6968846B2 (en) * 2002-03-07 2005-11-29 Stereotaxis, Inc. Method and apparatus for refinably accurate localization of devices and instruments in scattering environments
US20050020911A1 (en) * 2002-04-10 2005-01-27 Viswanathan Raju R. Efficient closed loop feedback navigation
US7008418B2 (en) * 2002-05-09 2006-03-07 Stereotaxis, Inc. Magnetically assisted pulmonary vein isolation
US20040096511A1 (en) * 2002-07-03 2004-05-20 Jonathan Harburn Magnetically guidable carriers and methods for the targeted magnetic delivery of substances in the body
US20060114088A1 (en) * 2002-07-16 2006-06-01 Yehoshua Shachar Apparatus and method for generating a magnetic field
US20060116633A1 (en) * 2002-07-16 2006-06-01 Yehoshua Shachar System and method for a magnetic catheter tip
US20040019447A1 (en) * 2002-07-16 2004-01-29 Yehoshua Shachar Apparatus and method for catheter guidance control and imaging
US20040157082A1 (en) * 2002-07-22 2004-08-12 Ritter Rogers C. Coated magnetically responsive particles, and embolic materials using coated magnetically responsive particles
US20040068173A1 (en) * 2002-08-06 2004-04-08 Viswanathan Raju R. Remote control of medical devices using a virtual device interface
US20040186376A1 (en) * 2002-09-30 2004-09-23 Hogg Bevil J. Method and apparatus for improved surgical navigation employing electronic identification with automatically actuated flexible medical devices
US20040158972A1 (en) * 2002-11-07 2004-08-19 Creighton Francis M. Method of making a compound magnet
US20040133130A1 (en) * 2003-01-06 2004-07-08 Ferry Steven J. Magnetically navigable medical guidewire
US20040249263A1 (en) * 2003-03-13 2004-12-09 Creighton Francis M. Magnetic navigation system and magnet system therefor
US20040249262A1 (en) * 2003-03-13 2004-12-09 Werp Peter R. Magnetic navigation system
US20040260172A1 (en) * 2003-04-24 2004-12-23 Ritter Rogers C. Magnetic navigation of medical devices in magnetic fields
US20050043611A1 (en) * 2003-05-02 2005-02-24 Sabo Michael E. Variable magnetic moment MR navigation
US6980843B2 (en) * 2003-05-21 2005-12-27 Stereotaxis, Inc. Electrophysiology catheter
US20050065435A1 (en) * 2003-07-22 2005-03-24 John Rauch User interface for remote control of medical devices
US20050119687A1 (en) * 2003-09-08 2005-06-02 Dacey Ralph G.Jr. Methods of, and materials for, treating vascular defects with magnetically controllable hydrogels
US20050113812A1 (en) * 2003-09-16 2005-05-26 Viswanathan Raju R. User interface for remote control of medical devices
US20050096589A1 (en) * 2003-10-20 2005-05-05 Yehoshua Shachar System and method for radar-assisted catheter guidance and control
US20050182315A1 (en) * 2003-11-07 2005-08-18 Ritter Rogers C. Magnetic resonance imaging and magnetic navigation systems and methods
US20050256398A1 (en) * 2004-05-12 2005-11-17 Hastings Roger N Systems and methods for interventional medicine
US20060041180A1 (en) * 2004-06-04 2006-02-23 Viswanathan Raju R User interface for remote control of medical devices
US20060041181A1 (en) * 2004-06-04 2006-02-23 Viswanathan Raju R User interface for remote control of medical devices
US20060041179A1 (en) * 2004-06-04 2006-02-23 Viswanathan Raju R User interface for remote control of medical devices
US20060041178A1 (en) * 2004-06-04 2006-02-23 Viswanathan Raju R User interface for remote control of medical devices
US20060036125A1 (en) * 2004-06-04 2006-02-16 Viswanathan Raju R User interface for remote control of medical devices
US20060025679A1 (en) * 2004-06-04 2006-02-02 Viswanathan Raju R User interface for remote control of medical devices
US20060009735A1 (en) * 2004-06-29 2006-01-12 Viswanathan Raju R Navigation of remotely actuable medical device using control variable and length
US20060036163A1 (en) * 2004-07-19 2006-02-16 Viswanathan Raju R Method of, and apparatus for, controlling medical navigation systems
US20060144407A1 (en) * 2004-07-20 2006-07-06 Anthony Aliberto Magnetic navigation manipulation apparatus
US20060144408A1 (en) * 2004-07-23 2006-07-06 Ferry Steven J Micro-catheter device and method of using same
US20060074297A1 (en) * 2004-08-24 2006-04-06 Viswanathan Raju R Methods and apparatus for steering medical devices in body lumens
US20060058646A1 (en) * 2004-08-26 2006-03-16 Raju Viswanathan Method for surgical navigation utilizing scale-invariant registration between a navigation system and a localization system
US20060079812A1 (en) * 2004-09-07 2006-04-13 Viswanathan Raju R Magnetic guidewire for lesion crossing
US20060079745A1 (en) * 2004-10-07 2006-04-13 Viswanathan Raju R Surgical navigation with overlay on anatomical images
US20060100505A1 (en) * 2004-10-26 2006-05-11 Viswanathan Raju R Surgical navigation using a three-dimensional user interface
US20060094956A1 (en) * 2004-10-29 2006-05-04 Viswanathan Raju R Restricted navigation controller for, and methods of controlling, a remote navigation system
US20060093193A1 (en) * 2004-10-29 2006-05-04 Viswanathan Raju R Image-based medical device localization

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060160888A1 (en) * 2004-12-09 2006-07-20 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
US8628796B2 (en) 2004-12-09 2014-01-14 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
US20080112895A1 (en) * 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
US20090181080A1 (en) * 2007-08-06 2009-07-16 Insys Therapeutics Inc. Oral cannabinnoid liquid formulations and methods of treatment

Also Published As

Publication number Publication date
US20030100602A1 (en) 2003-05-29
US6703418B2 (en) 2004-03-09
US20040209944A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
US20070088077A1 (en) Appetite stimulation and reduction of weight loss in patients suffering from symptomatic hiv infection
Kligler et al. Peppermint oil
US5498631A (en) Method for treatment of menopausal and premenstrual symptoms
CA2386215C (en) Method for treatment of chronic venous insufficiencies using an extract of red vine leaves
US6248307B1 (en) Compositions and treatment for alleviation of symptoms associated with menopause
EP0629400B1 (en) Idebenone compositions for treating Alzheimer's disease
EP0654271B1 (en) Pharmaceutical composition for treating aids
KR19980701720A (en) Combination medicine for the treatment of migraine and other diseases containing sesquiterpene lactones and vitamin B complex
US4833154A (en) Natural sleeping pill to prevent and alleviate insomnia
JP2943247B2 (en) Hypnosis / Sedative
KR100420673B1 (en) Nasal administration to treat delayed nausea
WO1993024125A1 (en) Δ-8-tetrahydro-cannabinol as antiemetic
EP0190851B1 (en) Improved antiinflammatory composition
IE904084A1 (en) Treatment of depression
EP1476160B1 (en) Pharmaceutical combination of artesunate and mefloquine for therapy of malaria
HEIM et al. Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy‐induced nausea and vomiting
CASSILETH et al. Antiemetic efficacy of high-dose dexamethasone in induction therapy in acute nonlymphocytic leukemia
US4265887A (en) Composition and method for treatment of hemorrhoids
KR20010034150A (en) Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate
CN1434710A (en) Specific therapeutic composition for treating AIDS
Glass Treatment of rattlesnake bites
AU2001228790B2 (en) A combination kit used in the treatment of malaria containing chloroquine and 3-(1-(((4-((6-methoxy-8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3H)furanone enthalt
GB2129299A (en) Pharmaceutical compositions
Petry et al. Medicinal herbs: answers and advice, part 1
DAVIS Thiabendazole in Pinworm Infestations: II. Comparison of Single and Intermittent Therapy, Long-Term Follow-Up, and Evaluation of New Dosage Form

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIMED PHARMACEUTICALS, LLC, GEORGIA

Free format text: CHANGE OF NAME;ASSIGNOR:UNIMED PHARMACEUTICALS, INC.;REEL/FRAME:020654/0154

Effective date: 20071228

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION